Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

MLA

Scagliotti, Giorgio V., et al. “Sunitinib plus Erlotinib versus Placebo plus Erlotinib in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 30, no. 17, June 2012, pp. 2070–78. EBSCOhost, https://doi.org/10.1200/JCO.2011.39.2993.

APA

Scagliotti, G. V., Krzakowski, M., Szczesna, A., Strausz, J., Makhson, A., Reck, M., Wierzbicki, R. F., Albert, I., Thomas, M., Miziara, J. E. A., Papai, Z. S., Karaseva, N., Thongprasert, S., Portulas, E. D., von Pawel, J., Zhang, K., Selaru, P., Tye, L., Chao, R. C., & Govindan, R. (2012). Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 30(17), 2070–2078. https://doi.org/10.1200/JCO.2011.39.2993

Chicago

Scagliotti, Giorgio V, Maciej Krzakowski, Aleksandra Szczesna, Janos Strausz, Anatoly Makhson, Martin Reck, Rafal F Wierzbicki, et al. 2012. “Sunitinib plus Erlotinib versus Placebo plus Erlotinib in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30 (17): 2070–78. doi:10.1200/JCO.2011.39.2993.